GLP1R and multiple endocrine neoplasia type 2: Based on preclinical studies that demonstrated an increased risk of medullary thyroid cancer, GLP-1 RA is contraindicated in patients with personal or family history of multiple endocrine neoplasia type 2 or medullary thyroid cancer.